RxDoctor Payments Data

Suzanne Jadico, MD

Ophthalmology · Princeton, NJNPI 1376744342

Payments from drug & device makers

$3,512in general payments, 2019–2025

Across 109 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Sight Sciences, Inc.$374
  • AbbVie$367
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$155
  • Novartis$142
  • Bausch & Lomb Americas Inc.$124
  • plus $843 from 13 others

What the payments were for

  • Food & beverage$3,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,512 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$488,969
Medicare patients
1,377
Services billed
3,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$98,454
XiidraLifitegrast29$56,429
MieboPerfluorohexyloctane/Pf28$30,672
LumiganBimatoprost43$24,836
CequaCyclosporine18$18,300
ProlensaBromfenac Sodium45$15,468
Cyclosporine17$15,032
CombiganBrimonidine Tartrate/Timolol12$9,818
Travatan ZTravoprost23$8,423
TyrvayaVarenicline Tartrate11$8,317
RocklatanNetarsudil Mesylat/Latanoprost11$6,874
Travoprost26$6,312
Bromfenac Sodium22$5,524
Prednisolone Acetate68$3,132
Timolol Maleate57$3,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$367$133,109116 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$124$87,10057 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$155$18,51269 claims
Sun Pharmaceutical Industries Inc.Cequa$75$18,30018 claims
NovartisTravatan Z$142$8,42323 claims
Oyster Point Pharma, Inc.Tyrvaya$13$8,31711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →